Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment. Early and accurate detection of AD is crucial for timely intervention and effective treatment. Biomarkers such as amyloid-beta and tau proteins, genetic markers like the APOE genotype, and neuroimaging findings are essential for AD diagnosis and prognosis, but their complex interactions require advanced analytical tools. AI has emerged as a transformative tool in healthcare, offering advanced computational techniques to analyze complex biomarker data with enhanced precision. This review paper explores the advancements in diagnosing Alzheimer's disease (AD) using artificial intelligence (AI) techniques. In the paper, we discuss the importance of diagnosing AD accurately and the potential benefits of using AI techniques for the early and accurate detection of AD. We emphasize the significance of AI in optimizing biomarker analysis for AD detection, discussing the challenges in their implementation and future implications. AI technologies can transform AD detection by significantly improving diagnostic imaging techniques, identifying key biomarkers, and standardizing the analysis of complex neuroimaging data. In the paper, we also highlight the critical role of AI in addressing challenges associated with integrating new technologies into clinical practice and providing effective solutions for consistent and reliable AD detection techniques.
Previous Article in event
Next Article in event
Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision
Published:
14 November 2024
by MDPI
in The 28th International Electronic Conference on Synthetic Organic Chemistry
session Computational Chemistry
Abstract:
Keywords: Alzheimer's disease detection; artificial intelligence; biomarker analysis; neurodegenerative disorders; early diagnosis
Comments on this paper
Jesse Pinkman
6 January 2025
What specific AI techniques or algorithms have shown the most promise in analyzing biomarkers like amyloid-beta and tau proteins for early Alzheimer's disease detection?
Zoya Iftekhar
14 January 2025
AI techniques like deep learning, particularly CNNs and RNNs, have shown significant potential in analyzing biomarkers such as amyloid-beta and tau proteins. CNNs are highly effective in processing imaging data (e.g., PET and MRI), while RNNs handle longitudinal biomarker trends for disease progression analysis. Multi-modal models that integrate imaging, cerebrospinal fluid (CSF), and blood biomarkers have proven valuable in improving early detection accuracy. Explainable AI methods, such as SHAP and LIME, provide insights into biomarker contributions, enhancing model transparency and clinical trust. These advancements demonstrate the transformative role of AI in early Alzheimer's diagnosis.
Ophelia Arias
15 January 2025
AD symptoms are indeed common in practice scratch games online. But the analytical content is really great for further research and access. Explore and experience from basic to advanced knowledge. Exchange to learn a lot.